32 results about "Rhinovirus" patented technology

The invention relates to the technical field of biology, in particular to a primer probe combination product for respiratory tract infection detection. A plurality of specific primers and self-quenching probes are integrated in a single reaction system; simultaneous, rapid and rapid detection on 15 respiratory pathogens (including influenza A virus, influenza B virus, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, mycoplasma pneumoniae, parainfluenza virus, rhinovirus, enterovirus, coronavirus, adenovirus, metapneumovirus, bordetella pertussis, bocavirus, chlamydia pneumoniae and chlamydia psittaci) is realized. The detection is accurate.

The application provides a quality control for detecting respiratory pathogen nucleic acid, which comprises any one or more of the following respiratory pathogens: coronavirus, influenza virus, adenovirus, Mycoplasma pneumoniae, Streptococcus pneumoniae, rhinovirus or / and Legionella pneumophila. The full-length genome sequence of the coronavirus is divided into 6 target fragments, each with a length of 4000-5500 bp. The quality control of the application covers all detection target sequences (or target points) of the coronavirus, has a wide coverage, comprehensively detects target points, and does not have the phenomenon of missed detection. The quality control of the application contains main respiratory pathogen infections, has a wide range, and uses real virus samples and lentivirus samples as raw materials, and has more accurate detection target points. The preparation of the coronavirus quality control of the application integrates the target gene sequence into the host genome through the lentivirus vector, knocks out the self-replication gene in the preparation process, and has a "self-inactivation" ability, so that the recombinant lentivirus cannot replicate in the target cells and infect other cells.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

Broad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting to viral resistance. The antiviral compositions are useful for treatment of diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, and the non-enveloped rhinovirus.

The present disclosure provides a primer pair for detecting rhinovirus, comprising a forward primer and a reverse primer directed to a 5' untranslated region (5' UTR), and the 5' UTR comprises a nucleotide sequence as shown in any one of SEQ ID NOs: 21 to 25. The forward primer has a length of 12 to 30 nucleotides and is corresponding to a nucleotide sequence between positions 1 to 70 of any one of SEQ ID NOs: 21 to 25. The reverse primer has a length of 12 to 30 nucleotides and is complementary to a nucleotide sequence between positions 180 to 204 of any one of SEQ ID NOs: 21 to 25. The present disclosure also provides a kit for detecting rhinovirus comprising the aforementioned primer pair, and a method for detecting rhinovirus using the aforementioned primer pair.

The present invention relates to a bifunctional peptide comprising a virus-binding portion (2) and a mucin-binding portion (1) covalently linked to the virus-binding portion (2). The virus-binding portion is selected from peptides that bind to SARS-CoV-2, influenza A virus, influenza B virus, rhinovirus and other enteroviruses, human parainfluenza virus, and / or metapneuvirus. The mucin-binding portion is selected from lectins such as trefoil factor 3.

The present invention discloses a nucleic acid detection kit for simultaneously detecting 9 respiratory pathogens based on a common qPCR detection platform, comprising the following non-mixing: reaction solution A, reaction solution B, and reaction solution C. Reaction solution A includes forward and reverse primers and fluorescent probes for influenza A virus, influenza B virus, and respiratory syncytial virus; reaction solution B includes forward and reverse primers and fluorescent probes for human parainfluenza virus, Mycoplasma pneumoniae, and the new coronavirus; reaction solution C includes forward and reverse primers and fluorescent probes for human respiratory adenovirus, human respiratory rhinovirus / enterovirus, and Bordetella pertussis. The fluorescent groups of the fluorescent probes used for different pathogens in the same reaction solution are different. The nucleic acid detection kit for simultaneously detecting 9 respiratory pathogens based on a common qPCR detection platform of the present invention has high specificity and high sensitivity, and is suitable for rapid detection of respiratory pathogens.

Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and / or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-COV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.

This invention discloses a multiplex qPCR kit for the simultaneous detection of six respiratory pathogens. The multiplex qPCR kit of this invention can simultaneously detect six common respiratory pathogens: adenovirus, human bocavirus, respiratory syncytial virus, mycoplasma pneumoniae, rhinovirus, and chlamydia pneumoniae. It has the advantages of high specificity, high sensitivity, good repeatability, and is unaffected by interfering substances. Furthermore, the kit is simple to operate and quick to use for detecting adenovirus, human bocavirus, respiratory syncytial virus, mycoplasma pneumoniae, rhinovirus, or chlamydia pneumoniae. It can simultaneously detect these six different common respiratory pathogens using a two-tube reaction system, and the detection results are accurate. It is suitable for rapid clinical detection of respiratory pathogens, which helps in timely and accurate treatment of the infecting pathogens.

To provide methods, compositions, and kits for detecting Adenovirus, Metapneumovirus, and / or Rhinovirus nucleic acid.SOLUTION: The disclosed disclosure is related to methods, compositions, and kits for targeting Adenovirus, Metapneumovirus, and / or Rhinovirus nucleic acid. Compositions include amplification oligomers and / or detection probe oligomers. Kits and methods comprise at least one of these oligomers. Methods include uniplex and multiplex amplification and detection reactions.SELECTED DRAWING: None

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

The invention belongs to the field of biological medicine, and discloses a broad-spectrum anti-enterovirus peptidomimetic 2CA-1 targeting enterovirus 2C protein and application of the broad-spectrum anti-enterovirus peptidomimetic 2CA-1. The 2CA-1 can be accurately butted to 2C protein binding pockets of EV71 and CVB3, the helicase activity of the 2CA-1 is effectively inhibited, and the 2CA-1 shows a strong and broad-spectrum antiviral effect on various pathogens such as coxsackie virus, EV-D68 and rhinovirus on the cellular level. More importantly, the 2CA-1 realizes a druggability breakthrough of excellent oral bioavailability in an animal model, and the in-vivo virus load can be remarkably reduced after oral administration. The invention provides an antiviral candidate drug with high-efficiency broad-spectrum activity and ideal oral administration characteristics, and has a wide application prospect.

The present disclosure provides a set of primers and optional probes for identifying the presence of alpha-coronavirus, beta-coronavirus, SARS-CoV-2, adenovirus, chlamydia pneumoniae, influenza A, influenza B, metapneumovirus, rhinovirus / enterovirus, mycoplasma, Bordetella, parainfluenza, and respiratory syncytial virus (RSV), the present invention relates to nucleic acid probes, which may be included with a cartridge (e.g., in a kit) or in a cartridge, for automated detection of these pathogens by nucleic acid amplification. The disclosure also provides related detection methods, as well as kits, systems, and kits useful in such methods.

The invention relates to the technical field of biological detection, in particular to a primer and probe combination for joint detection of seven pathogens, a kit and application. The primer and probe combination comprises primers and probes for specifically detecting the following pathogens: novel coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus, mycoplasma pneumoniae, rhinovirus and adenovirus, and nucleotide sequences are shown as SEQ ID NO: 1-24. Based on the primer and probe combination of the multiple system, seven targets can be simultaneously detected in one sample within 30 minutes. In addition, the sensitivity of the multiple systems is high, and the lowest detection limit is 500 copies / mL; and the kit has good specificity and has no cross reaction with other pathogens causing the same symptom. In addition, a PCR reagent comprising the primer and probe combination can be freeze-dried, a nucleic acid elution product to be detected is adopted to redissolve the PCR reagent during detection, and closed amplification is performed on a micro-fluidic chip.

Compounds and treatment methods with dipeptidyl compounds exhibiting antiviral activity and / or inhibition of viral replication against viruses by inhibiting 3CL protease, particularly those belonging to picornavirus, the compounds having a formula:(I) or (I)*.

The present invention relates to the use of bacterial compositions having an arginine deiminase activity (inhibition of nitric oxide synthase by conversion of L-arginine to L-citrulline) of 1-1,000 μmol L-citrulline / h / g composition and a sphingomyelinase (ceramide generation) activity of 0.01-1.000 nmoles ceramides / h / g composition in the treatment and / or prophylaxis of airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (VRS), rhinoviruses, pneumoviruses, or respiratory failure induced or aggravated by viral infections, angina pectoris, pulmonary heart, respiratory distress, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure Pickwick syndrome, pulmonary hypertension, pneumonia or even cystic fibrosis (CF) aggravated by viral infections.

The invention relates to the technical field of biological detection, in particular to an LAMP primer composition, an HRV detection system, a kit for rapidly detecting human rhinoviruses and application, the LAMP primer composition comprises an outer primer pair, an inner primer pair and a loop primer pair, the outer primer pair comprises the human rhinoviruses F3 and the human rhinoviruses B3, the inner primer pair comprises the human rhinoviruses FIP and the human rhinoviruses BIP, and the loop primer pair comprises the human rhinoviruses F3 and the human rhinoviruses B3. The loop primer pair comprises a human rhinovirus LF and a human rhinovirus LB, the HRV detection system comprises the LAMP primer composition, and the kit comprises the HRV detection system. The LAMP primer composition with the optimal performance, the HRV detection system and the kit for rapidly detecting the human rhinovirus are provided for the first time, when the LAMP primer composition is used for detecting the HRV, the reaction time is only 15 minutes, the detection sensitivity is 200 copies / mL, and the LAMP primer composition has the advantages of being easy and convenient to operate, low in cost and the like and is suitable for rapid on-site detection.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The present invention provides methods for identifying the amino acid sequence of a native polyprotein from a group A or C rhinovirus that can be used as an immunogen capable of eliciting an immune response against rhinoviruses from multiple serotypes within the same group. The present invention also provides immunogenic compositions comprising at least one mRNA comprising a non-native, optimized nucleic acid encoding a polyprotein identified by this method.

The disclosed disclosure is related to methods, compositions, and kits for targeting Adenovirus, Metapneumovirus, and / or Rhinovirus nucleic acid. Compositions include amplification oligomers and / or detection probe oligomers. Kits and methods comprise at least one of these oligomers. Methods include uniplex and multiplex amplification and detection reactions.

The application discloses a construction method of Aedes albopictus Aa01 cell line and susceptible cell model of Decapod iridovirus 1, and belongs to the technical field of virology and aquaculture disease prevention and control, wherein the Aedes albopictus Aa01 cell line is preserved in the China Center for Type Culture Collection of Wuhan University, and the preservation number is CCTCC NO: C202648. The method for constructing the DIV1 susceptible cell model based on the above cell line comprises the following steps: culturing the Aedes albopictus Aa01 cell line, and subculturing or using for virus inoculation when the density reaches 80%-90%; inoculating the DIV1 into the Aedes albopictus Aa01 cell line, removing the virus liquid after virus adsorption, and adding cell maintenance liquid for continuous culture; and observing the cytopathic effect CPE, collecting the cell culture when the CPE reaches 70%-80%, and obtaining the amplified DIV1 virus liquid. The DIV1 susceptible cell model constructed by the method can solve the problem that there is currently a lack of stable and continuously subcultured DIV1 in vitro culture.

The present invention provides a method for identifying the amino acid sequence of a naturally occurring polyprotein from a group A or C rhinovirus that can be used as an immunogen capable of eliciting an immune response against rhinoviruses from multiple serotypes within the same group. The invention also provides immunogenic compositions that comprise at least one mRNA comprising a non-naturally occurring optimized nucleic acid encoding a polyprotein identified by this method.

This article describes the use of phenol in the treatment of microbially induced dyspnea, specifically viral dyspnea, in a human patient, where the phenol is administered parenterally. The dyspnea is associated, in particular, with Acute Respiratory Distress Syndrome (ARDS). The viral infection is caused, in particular, by a virus selected from the group consisting of coronaviruses, influenza, Ebola, respiratory syncytial virus, HIV, Lassa virus, and rhinovirus. The phenol is administered parenterally, specifically subcutaneously or intravenously.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

The invention discloses a human rhinovirus susceptibility evaluation method and device, electronic equipment and a storage medium, which are used for solving the technical problem that the currently adopted human rhinovirus detection method cannot evaluate the human rhinovirus susceptibility of an individual in advance. The method comprises the following steps: acquiring a baseline blood transcriptome of a subject queue and a real susceptibility condition of a human rhinovirus; performing characteristic gene screening on the baseline blood transcriptome based on differential expression analysis and multi-dimensional joint interaction analysis to obtain a characteristic genome; extracting expression quantity data of a feature genome from the baseline blood transcriptome as a feature data set, and training a double-layer susceptibility evaluation model based on the feature data set and a real susceptibility condition; acquiring a to-be-detected baseline blood transcription sample, and extracting expression quantity data of the characteristic genome from the to-be-detected baseline blood transcription sample as a to-be-detected sample; and inputting a to-be-detected sample into the double-layer susceptibility evaluation model for human rhinovirus susceptibility prediction to obtain a susceptibility evaluation result.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

The invention discloses a reagent for distinguishing enteroviruses and rhinoviruses, a kit and application. The reagent comprises a first primer probe group for detecting the enteroviruses and a second primer probe group for detecting the rhinoviruses, the first primer probe group comprises a first upstream primer as shown in SEQ ID NO.1, a first downstream primer as shown in SEQ ID NO.2 and a first probe as shown in SEQ ID NO.3; the second primer probe group comprises a second upstream primer as shown in SEQ ID NO. 4, a third upstream primer as shown in SEQ ID NO. 5, a second downstream primer as shown in SEQ ID NO. 6 and a second probe as shown in SEQ ID NO. 7. The human enterovirus and the human rhinovirus can be simultaneously detected and accurately distinguished through a single tube, the defect that the human enterovirus and the human rhinovirus are subjected to cross reaction in the detection process is also overcome, false detection is prevented, the omission ratio is reduced, good specificity, inclusiveness, sensitivity and anti-interference performance are achieved, and the accuracy and reliability of detection and distinguishing are improved.

The invention belongs to the technical field of medicines, and discloses application of fumaric acid protoicellamate in preparation of medicines for preventing and treating respiratory virus infectious diseases. The invention particularly relates to application of a natural product fumaric acid protoicellamate or a metabolite thereof in vivo as an active ingredient in preparation of drugs with broad-spectrum antiviral activity and prevention and treatment of virus infectious diseases. The invention also discloses a medicine taking the trans-butene protoicellamate or the analogue thereof as an active ingredient. The traditional Chinese medicine composition can be used for preventing and treating respiratory virus infection such as human respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human rhinovirus (HRV), influenza virus, coronavirus, parainfluenza virus, measles virus, parotitis virus, rubella virus, adenovirus, cytomegalovirus, enterovirus, herpes simplex virus, varicella-zoster virus and the like; and infection of enteroviruses such as coxsackie virus, echovirus and the like can be prevented and treated, and a new drug treatment scheme is provided for clinical viral infection.

The disclosed disclosure is related to methods, compositions, and kits for targeting Adenovirus, Metapneumovirus, and / or Rhinovinis nucleic acid. Compositions include amplification oligomers and / or detection probe oligomers. Kits and methods comprise at least one of these oligomers. Methods include uniplex and multiplex amplification and detection reactions.

Self-adjuvanting vaccine compositions comprising at least one modified immunogen via in vitro glycosylation methods that provide a rational approach for generating glycosylated versions of immunogens via the reducing end of a linear carbohydrate, the reducing end containing an N-acyl-2-amino moiety. Self-adjuvanting vaccine compositions comprising a plurality of heterologous immunogens associated with a multivalent carrier, wherein at least one immunogen is glycosylated to allow for mucosal delivery. Self-adjuvanting vaccine compositions comprising multivalent carriers and related methods using the self-adjuvanting vaccine compositions in various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing a bacterial, viral, fungal, or protozoan infection. Pathogens for which this approach may be useful include, but are not limited to, influenza viruses, rhinoviruses, human immunodeficiency viruses (HIV), respiratory syncytial virus (RSV), coronaviruses, Babesia, Borrelia, Neisseria, and Chlamydia, and the related diseases thereof.